株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Ibodutant (過敏性腸症候群) - 2023年までの予測と市場分析

Ibodutant (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 325979
出版日 ページ情報 英文 56 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Ibodutant (過敏性腸症候群) - 2023年までの予測と市場分析 Ibodutant (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
出版日: 2014年12月31日 ページ情報: 英文 56 Pages
概要

当レポートでは、過敏性腸症候群 (IBS) の治療薬であるIbodutantについて調査しており、疾患の概要と疫学、疾患の管理、競合情勢、アンメットニーズと機会、パイプライン評価、主要企業の情報、今後の市場見通しなどを提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
  • 分類
  • 症状
  • 予後
  • 生活の質 (QOL)

第4章 疾患の管理

  • 疾患と治療の概要
    • 診断
    • 治療ガイドラインと主な処方薬
    • 臨床診療

第5章 競合評価

  • 概要

第6章 アンメットニーズと機会

  • 概要
  • より効果的な薬物療法
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • IBS Dタイプの治療法
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • IBS Mタイプの治療法
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • 腹痛と膨満感の症状に対処する治療法
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • IBSの診断率の向上
    • アンメットニーズ
    • ギャップ分析
    • 機会

第7章 パイプライン評価

  • 概要
  • 臨床開発における有望な治療薬

第8章 Ibodutant (MEN-15596)

  • 概要
  • 有効性
  • 安全性
  • 投与と処方
  • 潜在的な臨床的・商業的位置付け
  • SWOT分析
  • 予測

第9章 付録

目次
Product Code: GDHC522DFR

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Ibodutant is being developed by Menarini for the treatment of women with IBS-D. The Phase III program for ibodutant was initiated in Q1 2014 with two Phase III clinical trials, a 12-week study and a 52-week study, both of which were designed to evaluate the efficacy and safety of this product (Menarini, NCT02107196; Menarini, NCT02120027).

Scope

  • Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Ibodutant including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Ibodutant for the top 7 countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for IBS.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Ibodutant performance.
  • Obtain sales forecast for Ibodutant from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. More Effective Pharmacotherapies
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Therapies for the IBS-D Subtype
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Therapies for the IBS-M Subtype
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Therapies to Address Abdominal Pain and Bloating Symptoms
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Improved Diagnosis Rate for IBS
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Ibodutant (MEN-15596)

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning

8.6. SWOT Analysis

  • 8.7. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed IBS Patients
    • 9.4.2. General Pricing Assumptions
    • 9.4.3. Generic Erosion
    • 9.4.4. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Common Symptoms of IBS
  • Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
  • Table 3: Treatment Guidelines for IBS
  • Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014†
  • Table 5: Leading Branded Treatments for IBS, 2014
  • Table 6: Unmet Needs and Opportunities in IBS
  • Table 7: Drugs in Late-Stage Clinical Development for IBS, 2014
  • Table 8: Product Profile - Ibodutant
  • Table 9: Ibodutant SWOT Analysis, 2014
  • Table 10: Global IBS Sales Forecasts ($m) for Ibodutant, 2013-2023
  • Table 11: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Summary of Pharmacotherapies Used to Treat IBS
  • Figure 2: IBS - Phase IIb-III Pipeline, October 2014
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in IBS, 2013-2023
  • Figure 4: Clinical and Commercial Positioning of Ibodutant
Back to Top